# Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

> **NCT07392528** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Tianjin Huanhu Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders
- Multiple Sclerosis
- Myasthenia Gravis

## Interventions

- **DRUG:** QT-019C

## Key facts

- **NCT ID:** NCT07392528
- **Lead sponsor:** Tianjin Huanhu Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392528, "Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07392528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*